Stacey A. Cook leads liver disease research site in South Bend

Stacey A. Cook, site director and clinical research coordinator at ObjectiveHealth, oversees liver and digestive disease trials in South Bend, Indiana, while mentoring staff and patients. Her work has helped support research tied to semaglutide and reflects growing momentum in liver disease treatment.

Why it matters: - Stacey A. Cook’s work connects clinical research directly to care for patients with fatty liver disease, MASH/NASH, cirrhosis and related conditions. - The research site she leads contributes to multi-year studies that can expand treatment options for serious liver disease. - Her team’s work has helped support research tied to semaglutide, marketed as Wegovy and Ozempic, for liver disease treatment.

What happened: - Stacey A. Cook serves as Site Director and Clinical Research Coordinator at ObjectiveHealth in South Bend, Indiana. - Cook oversees the Digestive Research Alliance of Michiana, which runs clinical trials focused on digestive and liver disease. - Cook has worked in clinical research since 2020. - The site guides patients through diagnostic workups, investigational treatments and long-term study protocols. - Cook coordinates with GI specialists and family physicians to keep studies and patients on track.

The details: - The South Bend site conducts trials involving fatty liver disease, MASH/NASH and cirrhosis. - Cook reviews site finances, recruits patients and supervises staff as part of her leadership role. - Her career path included family medicine, cardiology, occupational health and podiatry before she moved into research leadership. - Cook earned an Associate of Science degree in Medical/Clinical Assisting from Brown Mackie College. - She became a Registered Medical Assistant before advancing into practice management and site leadership. - Cook said her approach to leadership is rooted in mastering the basics before taking on more responsibility. - She also said mentoring and developing staff has been central to her growth as a leader.

Between the lines: - Cook’s interest in healthcare followed the sudden loss of her father in 2008, which prompted her to reassess her life and career path. - Her story reflects a broader shift in liver disease care, where limited treatment options are now giving way to new medications and longer clinical trials. - The site’s recognition as one of the top-performing locations in the world across several clinical trials signals strong operational execution, not just scientific ambition. - Cook’s emphasis on patient outcomes and staff development suggests a leadership model that treats research performance and team building as linked goals.

What's next: - Cook expects continued progress as new therapies and long-term studies reshape liver disease treatment. - Her team will keep enrolling and supporting patients in ongoing clinical trials. - Cook remains focused on helping patients improve liver health, reduce medications when possible and move toward recovery.

The bottom line: - Stacey A. Cook has built a research career around patient care, team development and clinical trials that may help change how liver disease is treated in Indiana and beyond.

More information: Influential Women profile